Mereo BioPharma Group plc Result of Annual General Meeting (1696S)
21 June 2018 - 9:52PM
UK Regulatory
TIDMMPH
RNS Number : 1696S
Mereo BioPharma Group plc
21 June 2018
Mereo BioPharma Group plc
("Mereo" or the "Company")
Result of Annual General Meeting
London, 21 June 2018 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
and specialty diseases, announces that all resolutions proposed at
the Annual General Meeting held today were duly passed.
Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated
Adviser and Broker) +44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Rupert Walford
FTI Consulting (Public Relations Adviser) +44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations
Advisor to Mereo Biopharma) +01 (0) 212 213 0006
Lisa Burns
Steven Klass
About Mereo
Mereo is a multi-asset biopharmaceutical company focused on the
acquisition, development and commercialization of innovative
therapeutics that aim to improve outcomes for patients with rare
and specialty diseases. The portfolio consists of four
clinical-stage product candidates, each of which were acquired from
large pharmaceutical companies: BPS-804 for the treatment of
osteogenesis imperfecta; AZD-9668 for the treatment of severe
alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute
exacerbations of chronic obstructive pulmonary disease, or AECOPD;
and BGS-649 for the treatment of hypogonadotropic hypogonadism
("HH") in obese men. Each of the Company's product candidates has
generated positive clinical data for Mereo's target indication or
in a related indication. The Company's strategy is to selectively
acquire product candidates that have already received significant
investment from pharmaceutical companies and that have substantial
preclinical, clinical and manufacturing data packages. Since
inception the Company has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for three of the product
candidates and announced positive top-line results from its Phase 2
clinical trial of BCT-197 as an acute therapy for patients with
AECOPD in December 2017 and positive top-line data from its Phase
2b dose-ranging study with BGS-649 for the treatment of HH.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGUAVARWRANUAR
(END) Dow Jones Newswires
June 21, 2018 07:52 ET (11:52 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Mereo Biopharma Group Plc (London Stock Exchange): 0 recent articles
More Mereo Bioph News Articles